CDK4/6 Inhibitor Plus Aromatase Inhibitor Improves Progression-Free Survival in Metastatic Breast CancerOctober 12, 2016
Adding ribociclib to letrozole significantly improves progression-free survival for postmenopausal women with metastatic hormone receptor (HR)-positive breast cancer, compared with hormone therapy alone.
Questionnaires completed by patients with cancer considering enrollment in early-stage clinical trials indicate they may have unrealistic expectations.
Following the release of the Affordable Care Act (ACA) an increase in Hispanic women receiving breast cancer treatment and their related participation in clinical trials was observed.
Cancer research relies of patients with cancer to participate in clinical trials. However, many patients cite various fears and misconceptions — some supported by physicians - as reasons for why they decline to participate in clinical trials.
Improved cancer detection and advances in treatment mean larger numbers of older cancer patients are becoming survivors, combined with demographic trends. But older patients are underrepresented in clinical trials.
Patients participating in early-phase clinical trials should be assessed for sleep quality, as poor sleep quality is associated with greater fatigue, symptom burden, and mood disturbance.
Although Drugs@FDA may be useful for validating trial primary outcomes found on ClinicalTrials.gov, Drugs@FDA lacked information on secondary outcomes and adverse events, including deaths, according to an analysis of data from 100 trials available on both websites.
In a randomized phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with ALL whose disease had relapsed following standard therapies, qualified for stem cell transplants after treatment with the drug.
Results from the DECT trial indicate that a combination of epirubicin and trastuzumab improved outcomes in patients with HER2-positive breast cancer.
Outcomes in Clinical Trials Using Precision Medicine Demonstrate Effectiveness of Modality in Patients With CancerJune 20, 2016
A meta-analysis of hundreds of cancer clinical trials revealed that therapeutic approaches using precision medicine had improved responses and longer disease remission, even in phase I trials.
US FDA standards demand that surrogate end points used in clinical trials be "reasonably likely to predict" survival for accelerated approval, or be established proxies for survival for traditional approval; however, surrogate end points used frequently lack formal study.
Daratumumab in Combination With Standard-of-Care Treatment Significantly Improves Outcomes in Patients With Multiple MyelomaJune 15, 2016
Daratumumab in combination with the standard-of-care treatment regimen reduced risk of disease progression or death by 63% compared with the standard-of-care regimen alone in patients with multiple myeloma who had received at least 1 prior line of therapy.
A third clinical trial is beginning for phase I testing of SurVaxM, a cancer vaccine. This trial tests for safety and effectiveness of the vaccine in combination with lenalidomide as maintenance therapy for adults with multiple myeloma.
Prognostic Index Will Improve Clinical Practice Management of Patients With CLL and in Clinical TrialsJune 10, 2016
An international consortium devised an international prognostic index for chronic lymphocytic leukemia (CLL-IPI) that combines genetic, biochemical, and clinical parameters into a prognostic model to enable more targeted management of patients with CLL.
Physical exercise may have a direct effect on cancer that is as effective as drugs for treating patients with prostate cancer, even for those with advanced stages of the disease.
NETTER-1 trial results of the somatostatin analogue peptide, 177Lu-DOTA0-Tyr3-octreotate (177Lu-Dotatate), suggest a potential survival benefit in patients with advanced midgut neuroendocrine tumors (NETs), attendees at the ASCO 2016 Annual Meeting were told.
Patients whose treatment was based on the molecular characteristics of their particular tumor had significantly better outcomes compared with patients who did not.
Only 40 percent of those polled had favorable view of these studies, but the number rose when they received more information.
Chemoradiotherapy Showed No Survival Benefit Over Chemotherapy in Locally Advanced Pancreatic CancerMay 24, 2016
Researchers discovered no survival benefit of chemoradiotherapy over chemotherapy in treating locally advanced pancreatic cancer in the LAP01 Randomized Clinical Trial.
The experimental treatment LOXO-101 led to remarkable improvement for a 20-month-old girl whose rare pediatric cancer did not respond to surgery or chemotherapy.
Tumors of varied types of genetically defined cancer were significantly reduced by the drug LOXO-101, according to phase 1 study results.
A research unit created by oncology nurses trains nurses to provide high quality care to patients in oncology clinical trials.
A clinical trial infusion nurse orientation improves training for nurses so they can better care for patients participating in investigational trials.
Cancer stem cells that drive tumor growth were halved by MEDI-551, an experimental antibody treatment for multiple myeloma, according to results of a small preliminary clinical trial.
Shortened Radiation Therapy Schedule No Worse Than Conventional Radiotherapy in Low-Risk Prostate CancerApril 22, 2016
Treatment with a hypofractionated radiotherapy (HRT) schedule achieved similar efficacy as treatment with the longer, conventional RT (CRT) schedule in men with low-risk prostate cancer.
Adding panobinostat to radiotherapy appears safe, tolerable, and has preliminary efficacy for treating recurrent high-grade gliomas.
The social media platform Twitter could develop into a useful tool for communicating with the public about cancer clinical trials and for recruiting participants.
Combination therapy with durvalumab and tremelimumab demonstrated antitumor activity in 23% of 102 patients with lung cancer in a phase 1b trial, and toxicity was manageable.
No evidence that interferon is necessary or helpful in cases of melanoma with minimal metastasis to the lymph nodes, according to the final results of the Sunbelt Melanoma Trial.
Tumor growth may be substantially slowed by the novel therapy 177Lutetium-DOTATATE (Lutathera), according to early results from a phase III study of patients with previously treated, advanced midgut neuroendocrine tumors.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- How Physical Changes From Breast Cancer Affect Self-Image: Considerations for Clinicians
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Atypical Teratoid/rhabdoid Tumors: Challenges and Search for Solutions
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|